Johnson & Johnson COVID-19 vaccine candidate moves forward to phase 3
Johnson & Johnson today said that its COVID-19 vaccine candidate is moving to a global phase 3 clinical trial.
The JNJ-78436735 vaccine candidate, which was developed by J&J subsidiary Janssen Pharmaceutical Companies, will be administered to 60,000 volunteers at 215 clinical sites across three continents. The vaccine is believed to be the first COVID-19 candidate that would require just a single dose to spur immunity in patients.
The trial will be funded by Johnson & Johnson/Janssen, the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…